IEFM
NTLA icon

IQ EQ Fund Management’s Intellia Therapeutics NTLA Stock Holding History

IQ EQ Fund Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2M Buy
777,948
+53,662
+7% +$751K 0.84% 34
2026
Q1 		$9.29M Sell
724,286
-7,135
-1% -$90.9K 0.71% 41
2025
Q4 		$6.58M Buy
731,421
+236,953
+48% +$3.26M 0.45% 68
2025
Q3 		$8.54M Buy
494,468
+200,081
+68% +$2.46M 0.58% 54
2025
Q2 		$2.76M Buy
294,387
+188,178
+177% +$1.55M 0.25% 113
2025
Q1 		$755K Buy
106,209
+51,552
+94% +$521K 0.09% 211
2024
Q4 		$637K Buy
54,657
+31,626
+137% +$494K 0.08% 231
2024
Q3 		$473K Buy
23,031
+9,889
+75% +$228K 0.05% 264
2024
Q2 		$294K Buy
+13,142
New +$313K 0.03% 275

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

IQ EQ Fund Management's NTLA Position: Q2 2026 in Review

IQ EQ Fund Management increased its Intellia Therapeutics (NTLA) stake by 7.4% in Q2 2026, buying an estimated $751K and bringing the position to 777,948 shares worth $13.2M. The position accounts for 0.84% of the portfolio, ranked #34.

IQ EQ Fund Management first reported a position in NTLA in Q2 2024 and has held it in 9 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • IQ EQ Fund Management held 777,948 shares of Intellia Therapeutics worth $13.2M as of Q2 2026.
  • IQ EQ Fund Management bought 53,662 Intellia Therapeutics shares in Q2 2026, an estimated $751K.
  • Intellia Therapeutics made up 0.84% of IQ EQ Fund Management's portfolio in Q2 2026, its #34 holding.
  • IQ EQ Fund Management first reported a position in Intellia Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on IQ EQ Fund Management's 13F filing for Q2 2026, filed 31 Jul 2026.